Clinical Trial · NCT07101900

68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses

Overview

This is a prospective, single-center, single-arm, diagnostic phase 2 study in patients who have renal masses scheduled for surgical resection. The goal is to determine the sensitivity and specificity of 68Ga-NYM096 PET/CT in the detection of clear cell renal cell carcinoma using histopathological diagnosis as ground truth, in patients with operable renal masses.

Sponsor

Peking Union Medical College Hospital

Phase

Phase 2

ClinicalTrials.gov

NCT07101900

Drug / Compound

NYM096

Isotope(s):

Target(s):

CAIX

Ligand Class: Small Molecules

Eligibility

Inclusion

Surgical Contraindications:
Renal mass (solitary or multiple) with a maximum diameter ≥1 cm, confirmed by conventional imaging (ultrasound, non-contrast CT, contrast-enhanced CT, or MRI);
Scheduled for renal mass resection (partial or total nephrectomy, via open, laparoscopic, or robot-assisted techniques) within 1 month;

Exclusion

Exclusion criteria not yet provided.